Gastrointestinal
Partnership Aims to Bring Novel Gastroenterology Therapies to Worldwide Market
Partnership Aims to Bring Novel Gastroenterology Therapies to Worldwide Market
Parvus Therapeutics and Genentech have entered into a worldwide collaboration and licensing agreement for the development, manufacturing, and commercialization of treatments for inflammatory bowel disease, autoimmune liver diseases, and celiac disease using nanomedicines (Navacim) developed by Parvus.
Read More >>
FDA Officials Reject NDA, in Current Form, for Gastroparesis Treatment
FDA Approves TAS-102 for Treating Adults With Gastric/GEJ Cancer
FDA OKs Rifamycin for Travelers' Diarrhea Caused by Noninvasive E coli
Opioid-Induced Constipation
FDA Approves Eravacycline for Adults With Complicated Intra-Abdominal Infections
FDA OKs Eravacycline for Complicated Intra-Abdominal Infections
5 Things Pharmacists Should Know About the Recent Cyclospora Outbreak
View more articles >>
Clinical Trials
The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients
Applying Long-term Follow-up to Improve Patient Selection in Laparoscopic Anti-reflux Surgery
Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Cross-sectional Study.
Fermented Soy and Heartburn Symptom Relief
A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer
Multimedia: Videos
What Lifestyle Interventions Can Pharmacists Recommend to Avoid Stomach Upset?
What Lifestyle Interventions Can Pharmacists Recommend to Avoid Stomach Upset?
How Should Pharmacists Counsel Patients on PPI Use for Heartburn?
How Should Pharmacists Counsel Patients on PPI Use for Heartburn?
How New Agents are Helping Address Clostridium Difficile-Associated Diarrhea Concerns
How New Agents are Helping Address Clostridium Difficile-Associated Diarrhea Concerns
Acid Reflux: More Than a Nuisance
Acid Reflux: More Than a Nuisance